Improving brain cell health to prevent memory loss in Alzheimer's disease
Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease
This study is looking at new tiny compounds that could help a protein in brain cells work better, which might protect against neuron loss in Alzheimer's disease and improve memory and learning for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neurodon LLC NIH-funded |
| Lab location | 1 site (Crown Point, UNITED STATES) |
| Project ID | NIH-10934536 on NIH RePORTER |
What this research studies
This research focuses on developing new small molecule compounds that can enhance the function of a key protein involved in calcium regulation in brain cells. By targeting the underlying causes of neuron loss in Alzheimer's disease, the project aims to provide a potential disease-modifying therapy rather than just treating symptoms. The compounds have shown promise in preclinical models, demonstrating neuroprotection and improvements in learning and memory. Patients may benefit from these advancements if the compounds prove effective in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow or prevent the progression of Alzheimer's disease by protecting brain cells.
How similar studies have performed: While there have been many studies targeting amyloid-related pathways, this approach focusing on calcium handling in neurons is relatively novel and has not been widely tested in clinical settings.
Where this research is happening
Crown Point, UNITED STATES
- Neurodon LLC — Crown Point, United States (Active)
Researchers
- Principal investigator: Dahl, Russell — Neurodon LLC
- Study coordinator: Dahl, Russell
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.